Perturbations of Zinc Homeostasis and Onset of Neuropsychiatric Disorders.

This review looked at how problems with zinc levels in the body might be linked to brain conditions like autism, ADHD, and depression. Researchers found some evidence that zinc supplements (around 25-30mg daily) might help with depression treatment, and possibly help children with ADHD to a smaller degree. However, there isn't enough research to know if zinc supplements really work for these conditions, what the right doses are, or if they're safe long-term.

This narrative review examines the relationship between zinc homeostasis disruptions and neuropsychiatric disorders including autism spectrum disorder, ADHD, depression, and others. The authors conducted a targeted literature search to explore how zinc deficiency, excess, or transport problems may contribute to these conditions. Current evidence suggests modest benefits for zinc supplementation (25-30 mg/day) as an addition to depression treatment, with potential smaller benefits in pediatric ADHD. However, evidence for zinc as a biomarker for neuropsychiatric risk remains unconvincing.

The review highlights significant knowledge gaps regarding optimal dosing, long-term safety, and patient selection criteria for zinc supplementation across neuropsychiatric conditions.

Current evidence provides limited support for zinc supplementation in neuropsychiatric conditions. Clinicians should exercise caution given unclear optimal dosing and safety profiles. More rigorous randomised controlled trials are needed to establish efficacy and safety parameters before routine clinical implementation.

This was a narrative review using unsystematic search methods. The authors note lack of specific randomised controlled trials exploring zinc supplement efficacy. Questions remain unanswered regarding long-term safety, optimal dosing, and patient selection criteria for zinc supplementation.

Zinc (Zn) is a trace element essential for its catalytic, antioxidant, and immunomodulatory roles extending to synaptic signalling in the central nervous system. In this narrative review, we aim to offer the reader evidence linking perturbations of the Znhomeostasis, including deficiency, excess, or transportation anomalies, to neuropsychiatric conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BD). A targeted, unsystematic PubMed search followed by an extensive pearl-growing strategy was applied to further augment study selection based on the extensive expertise of study authors. Overall, most of the evidence currently available suggests a modest benefit for a Znsupplement of around 25-30 mg/day as an augmentation to MDD treatment, with potential benefits of smaller magnitude in paediatric ADHD.

Evidence for perturbations of Znas a biomarker of risk for these neuropsychiatric disorders remains unconvincing. The role of Znsupplements in the treatment of the selected conditions remains largely unknown due to the lack of specific, randomised controlled trials conducted to explore their efficacy. The long-term safety, optimal doses for specific applications, and the exploration of possible biomarkers to stratify patient selection to identify the optimal candidate for Znsupplements remain unanswered questions.